258 related articles for article (PubMed ID: 20530257)
1. Intact NKG2D-independent function of NK cells chronically stimulated with the NKG2D ligand Rae-1.
Champsaur M; Beilke JN; Ogasawara K; Koszinowski UH; Jonjic S; Lanier LL
J Immunol; 2010 Jul; 185(1):157-65. PubMed ID: 20530257
[TBL] [Abstract][Full Text] [Related]
2. Activation receptor-induced tolerance of mature NK cells in vivo requires signaling through the receptor and is reversible.
Bolanos FD; Tripathy SK
J Immunol; 2011 Mar; 186(5):2765-71. PubMed ID: 21263069
[TBL] [Abstract][Full Text] [Related]
3. Induction of NKG2D ligand expression on tumor cells by CD8
Hu J; Xia X; Gorlick R; Li S
Oncogene; 2019 Dec; 38(49):7433-7446. PubMed ID: 31427736
[TBL] [Abstract][Full Text] [Related]
4. Activating receptor NKG2D targets RAE-1-expressing allogeneic neural precursor cells in a viral model of multiple sclerosis.
Weinger JG; Plaisted WC; Maciejewski SM; Lanier LL; Walsh CM; Lane TE
Stem Cells; 2014 Oct; 32(10):2690-701. PubMed ID: 24898518
[TBL] [Abstract][Full Text] [Related]
5. Fratricide of natural killer cells dressed with tumor-derived NKG2D ligand.
Nakamura K; Nakayama M; Kawano M; Amagai R; Ishii T; Harigae H; Ogasawara K
Proc Natl Acad Sci U S A; 2013 Jun; 110(23):9421-6. PubMed ID: 23690625
[TBL] [Abstract][Full Text] [Related]
6. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
[TBL] [Abstract][Full Text] [Related]
7. Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8
Hu J; Bernatchez C; Zhang L; Xia X; Kleinerman ES; Hung MC; Hwu P; Li S
Cancer Immunol Res; 2017 Apr; 5(4):300-311. PubMed ID: 28223282
[TBL] [Abstract][Full Text] [Related]
8. A dual function of NKG2D ligands in NK-cell activation.
Cheney EE; Wise EL; Bui JD; Schreiber RD; Carayannopoulos LN; Spitzer D; Zafirova B; Polic B; Shaw AS; Markiewicz MA
Eur J Immunol; 2012 Sep; 42(9):2452-8. PubMed ID: 22740149
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of NK cell activity through TGF-beta 1 by down-regulation of NKG2D in a murine model of head and neck cancer.
Dasgupta S; Bhattacharya-Chatterjee M; O'Malley BW; Chatterjee SK
J Immunol; 2005 Oct; 175(8):5541-50. PubMed ID: 16210663
[TBL] [Abstract][Full Text] [Related]
10. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo.
Wiemann K; Mittrücker HW; Feger U; Welte SA; Yokoyama WM; Spies T; Rammensee HG; Steinle A
J Immunol; 2005 Jul; 175(2):720-9. PubMed ID: 16002667
[TBL] [Abstract][Full Text] [Related]
11. NK cells and gammadelta T cells mediate resistance to polyomavirus-induced tumors.
Mishra R; Chen AT; Welsh RM; Szomolanyi-Tsuda E
PLoS Pathog; 2010 May; 6(5):e1000924. PubMed ID: 20523894
[TBL] [Abstract][Full Text] [Related]
12. T cells gene-engineered with DAP12 mediate effector function in an NKG2D-dependent and major histocompatibility complex-independent manner.
Teng MW; Kershaw MH; Hayakawa Y; Cerutti L; Jane SM; Darcy PK; Smyth MJ
J Biol Chem; 2005 Nov; 280(46):38235-41. PubMed ID: 16169855
[TBL] [Abstract][Full Text] [Related]
13. Rae1 drives NKG2D binding-dependent tumor development in mice by activating mTOR and STAT3 pathways in tumor cells.
Zhao P; Yang L; Li X; Lu W; Lu F; Wang S; Wang Y; Hua L; Cui C; Dong B; Yu Y; Wang L
Cancer Sci; 2020 Jul; 111(7):2234-2247. PubMed ID: 32333709
[TBL] [Abstract][Full Text] [Related]
14. RAE1 ligands for the NKG2D receptor are regulated by STING-dependent DNA sensor pathways in lymphoma.
Lam AR; Bert NL; Ho SS; Shen YJ; Tang LF; Xiong GM; Croxford JL; Koo CX; Ishii KJ; Akira S; Raulet DH; Gasser S
Cancer Res; 2014 Apr; 74(8):2193-2203. PubMed ID: 24590060
[TBL] [Abstract][Full Text] [Related]
15. CD4(+) NKG2D(+) T cells induce NKG2D down-regulation in natural killer cells in CD86-RAE-1ε transgenic mice.
Lin Z; Wang C; Xia H; Liu W; Xiao W; Qian L; Jia X; Ding Y; Ji M; Gong W
Immunology; 2014 Mar; 141(3):401-15. PubMed ID: 24708417
[TBL] [Abstract][Full Text] [Related]
16. Expression of the RAE-1 family of stimulatory NK-cell ligands requires activation of the PI3K pathway during viral infection and transformation.
Tokuyama M; Lorin C; Delebecque F; Jung H; Raulet DH; Coscoy L
PLoS Pathog; 2011 Sep; 7(9):e1002265. PubMed ID: 21966273
[TBL] [Abstract][Full Text] [Related]
17. [Effects of NKG2D and its ligands RAE-1 and H60 on graft-versus-tumor response].
Li XF; Chen Q; Ye YB; Fan LF; Chen MS; Li JY; Chen HQ; Chen SP; Zhou ZF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Feb; 15(1):160-4. PubMed ID: 17490545
[TBL] [Abstract][Full Text] [Related]
18. Activation of V gamma 9V delta 2 T cells by NKG2D.
Rincon-Orozco B; Kunzmann V; Wrobel P; Kabelitz D; Steinle A; Herrmann T
J Immunol; 2005 Aug; 175(4):2144-51. PubMed ID: 16081780
[TBL] [Abstract][Full Text] [Related]
19. CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells.
Sauer M; Schuldner M; Hoffmann N; Cetintas A; Reiners KS; Shatnyeva O; Hallek M; Hansen HP; Gasser S; von Strandmann EP
Oncogene; 2017 Feb; 36(7):933-941. PubMed ID: 27477692
[TBL] [Abstract][Full Text] [Related]
20. Lysine acetylation of NKG2D ligand Rae-1 stabilizes the protein and sensitizes tumor cells to NKG2D immune surveillance.
Hu J; Xia X; Zhao Q; Li S
Cancer Lett; 2021 Apr; 502():143-153. PubMed ID: 33279621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
